Management of portal hypertension complications in PSVD - Paris PSVD Meeting

Value of the Information & Strength of the Argument

The presentation provides valuable insights into the current evidence and clinical practice for PSVD, a rare disease with limited data. The speaker systematically reviews complications, citing recent cohort studies and trials, and clearly distinguishes between established evidence and extrapolations from cirrhosis. He acknowledges the lack of randomized controlled trials for primary prophylaxis and the need for further research. The argumentation is balanced, weighing the benefits and risks of therapies, and emphasizes the importance of considering the unique pathophysiology of PSVD. The discussion of EUS-PPG as a novel tool is particularly valuable, offering a potential solution to the limitations of HVPG. Overall, the content is informative and clinically relevant, with a critical approach to evidence.

Scientific Rigor, Source Quality, Title Accuracy

The presentation demonstrates scientific rigor by referencing recent studies and guidelines, such as the Baveno criteria and EASL guidelines. The speaker appropriately notes the limitations of extrapolating from cirrhosis data and highlights areas where evidence is lacking. The title accurately reflects the content, which focuses on managing portal hypertension complications in PSVD. The speaker does not overstate findings and acknowledges the need for further research. The inclusion of a Q&A session adds depth, addressing practical clinical questions. Overall, the sources are credible and the content aligns with the title.

The title accurately reflects the content, which focuses on managing portal hypertension complications in PSVD.

8/10

Presentation by a recognized expert in hepatology, based on recent cohort studies and clinical trials, with clear distinction between established data and extrapolations. Limitations of evidence are acknowledged, and recommendations align with current guidelines.

Markers derived by PSI from the transcript: the creator did not define chapters.

• 00:00Introduction: The question of whether management of portal hypertension complications in PSVD should differ from cirrhosis.
• 02:00Prevalence of varices in PSVD and the need for screening endoscopy.
• 05:00Non-invasive assessment: spleen stiffness and bilirubin to rule out high-risk varices.
• 08:00Primary prophylaxis: beta-blockers for patients with clinically significant portal hypertension, based on PREDESCI trial.
• 10:00EUS-guided portal pressure gradient measurement: a direct measurement tool for PSVD.
• 12:00Acute variceal bleeding management: vasoactive drugs, antibiotics, endoscopy within 12 hours.
• 15:00Secondary prophylaxis: beta-blockers plus band ligation, with RCT data showing reduced rebleeding.
• 18:00TIPS for variceal bleeding: similar efficacy but lower encephalopathy risk; reserved for refractory cases.
• 20:00Ascites: occurs in 20-30%, often resolves after acute events; TIPS effective for refractory ascites.
• 22:00Hepatic encephalopathy: less common, associated with shunts; managed with lactulose/rifaximin.
• 24:00Portal vein thrombosis: high incidence, surveillance every 6 months, anticoagulation as first-line.
• 26:00Summary: management mostly mirrors cirrhosis, but new tools may enable tailored approaches.

• EASL Clinical Practice Guidelines on vascular liver diseases — Referenced for recommendations on PSVD management and portal vein thrombosis surveillance.
• Baveno VI and VII criteria for non-invasive assessment of portal hypertension — Mentioned as criteria used in cirrhosis but not applicable to PSVD.
• PREDESCI trial — Cited as evidence for primary prophylaxis with beta-blockers in compensated cirrhosis with clinically significant portal hypertension.
• Study on spleen stiffness for variceal screening in PSVD (VALDIG consortium) — Referenced for using spleen stiffness and bilirubin to rule out high-risk varices in PSVD.
• EUS-guided portal pressure gradient measurement study — Mentioned as a direct measurement tool for portal pressure in PSVD.

• EASL Clinical Practice Guidelines on vascular liver diseases — Aligns with recommendations for PSVD management and PVT surveillance.
• Baveno VII consensus on portal hypertension — Provides non-invasive criteria for cirrhosis, which the speaker notes are not applicable to PSVD.

• Study on HVPG in PSVD — HVPG underestimates portal pressure in PSVD, conflicting with its use in cirrhosis.